Responsible for AbbVie’s Glioblastoma (GBM) assets and for diagnostics (CDx) across the solid tumour portfolio. Responsible for building and implementing a medical strategy. Works closely with marketing and market access to build wider brand plan and build NICE submission dossiers. Regularly attends congresses to gather competitor insights and for KOL development opportunities and collaborations with global medical affairs. Works closely with medical science liaisons (MSL) to ensure unity and uniformity across UK Medical affairs.

Head-office medical advisor responsible for chronic myeloid leukaemia (CML) asset. Responsible for creating and implementing a medical strategy and supporting marketing and sales team with medical expertise and training. Responsible for all haematology investigator-initiated study (IIS) proposals. First-medical reviewer for all haematology materials.

Responsible for non-promotional activities across Pfizer Oncology portfolio. Responsibilities included key opinion leader engagement and mapping, reactive data dissemination and communication with external experts. Lead initiative to educate pathologists and clinical scientists on CDx in alk-rearranged lung cancer. Represented Pfizer in ABPI diagnostics project aiming to track all UK diagnostic tests in real time. Lead on compassionate access programme in the UK in a pre-license setting giving patients access to novel breast cancer treatment.

● Technical lead on the research and development of hybridisation-based sequencing panels for cancer diagnostics using Illumina’s MiSeq platform. ● Successfully developed and launched a myeloid cancer panel for the detection of haematological cancers (Myeloproliferative neoplasms).● Project planning from initial design to launch. ● Liaising with key opinion leaders (KOLs) for product design including panel customisations.● Writing training material for FASs, protocols and marketing material.● Training and technical support to customers in the UK and France (IGR) http://www.ogt.co.uk/products/1074_sureseq_myeloid_panel

● Research and development on a novel technology capable of isolating circulating tumour cells from peripheral blood for the diagnosis of cancer.● Experimental design.● Communication of results to a range of audiences.● Liaising with collaborators.● Phlebotomy and collection of clinical samples (NHS-accredited phlebotomist).